Provider Summary
Primary Uses
Complement-mediated disorders including PNH, aHUS, generalized myasthenia gravis, and NMOSD (indication depends on diagnosis) per label and payer criteria.
Mechanism of Action
Terminal complement inhibitor (C5) with extended duration, preventing complement-mediated hemolysis/tissue injury.
Pre-treatment / Baseline Requirement
Boxed warning risk: meningococcal infection. Vaccinate against meningococcal bacteria at least 2 weeks prior when feasible; REMS participation; educate on urgent infection symptoms; screen for active infection.
Common side effects
Headache, upper respiratory infections, nausea/diarrhea (varies by indication).
Serious adverse effects / key risks
Boxed warning: serious, life-threatening meningococcal infections; other serious infections with encapsulated organisms.
REMS & Vaccination
Meningococcal vaccination is required per REMS. If treatment must start before vaccines are effective, follow prescriber PI guidance regarding prophylactic antibiotics and urgent-start protocols.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
Meningitis risk
vaccination is required. Seek emergency care for sudden fever, severe headache, stiff neck, rash, confusion, or sensitivity to light.
What it treats
Complement-mediated disorders including PNH, aHUS, generalized myasthenia gravis, and NMOSD
How it works
Blocks complement (C5), preventing immune-mediated damage in certain rare conditions.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Headache, upper respiratory infections, nausea/diarrhea.
Get urgent help for:
Boxed warning: serious, life-threatening meningococcal infections; other serious infections with encapsulated organisms